Trial intelligence / Profile preview

Phase II neoadjuvant bevacizumab plus chemotherapy in initially unresectable advanced ovarian, tubal or peritoneal adenocarcinoma

2012-001144-22Phase 2Completed

Sponsor: Roche
Start: Sep 2012
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 2, randomised, open-label trial of bevacizumab in epithelial ovarian cancer (EOC), ovarian carcinosarcoma (OCS), primary peritoneal cancer (PPC) and 1 more (2 arms), sponsored by Roche. Primary endpoint: Complete macroscopic resection rate at interval debulking surgery. Started Sep 2012; status: completed.

Drugs

bevacizumab

Conditions

epithelial ovarian cancer (EOC)ovarian carcinosarcoma (OCS)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)

Beyond the preview

Go deeper on 2012-001144-22.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-001144-22.